Lyka Labs Limited

Corporate Office : Ground Floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036.
Phone : 022 6611 2200 / 244 /290 • Website : www.lykalabs.com • Email : enquiry@lykalabs.com

11th August, 2026

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001	National Stock Exchange of India Limited Exchange Plaza, G. Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051
Script Code: 500259	Script Code: LYKALABS

Sub: Submission of Revised Press Release on Unaudited Financial Results for the First Quarter ended June 30, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir / Madam,

With reference to our earlier submission of the Press Release on the Unaudited Financial Results of the Company for the quarter ended June 30, 2026, filed with the Stock Exchanges on August 10, 2026, we hereby submit a revised Press Release for the same period.

This revised submission corrects typographical errors regarding specific financial figures in the original press release. All other data in the release remains unchanged.

We kindly request that you take the revised press release on record and update it on your website for the information of members and investors. We deeply regret any inconvenience caused.

The above information will also be made available on the website of the Company at www.lykalabs.com

Thanking you,

Yours faithfully,
For **Lyka Labs Limited**

SHAILENDRA KUMAR AGRAWAL
Digitally signed by SHAILENDRA KUMAR AGRAWAL
Date: 2026.08.11 15:03:01 +05'30'

Shailendra Agrawal
Company Secretary and Compliance Officer
Encl.: as above

Press Release

Lyka Labs Limited Q1 FY27 Unaudited Financials Results

Mumbai, August 10, 2026 :

Lyka Labs Limited today announced its unaudited financial results for the first quarter ended 30th June 2026 of the financial year 2026-27

Key Financials of Q1 FY27

- Stanalone Net Total Income up 42.67% at Rs. 4272.79 Lacs.
- Consolidated Net Total Income up 26.95% at Rs. 4272.79 Lacs.
- Domestic Revenue up 15.91% at Rs. 2652.11 Lacs.
- Export Revenue up 68.03 % at Rs. 1483.42 Lacs.
- Standalone EBITDA margin @ 11.84% in Q1 FY27 as against 14.16% in Q1 FY26
- Consolidated EBITDA margin @ 11.74% in Q1 FY27 as against 13.07% in Q1 FY26
- Standalone Net Profit up 159.06 % at Rs. 210.03 Lacs.
- Consolidated Net Profit up 105.44 % at Rs. 204.66 Lacs.

Standalone Q1 FY27 at a glance **(Rs. In lacs)**

Particulars	Q1 FY27	Q1 FY26	Growth in %
Revenue from Operations	4230.94	2917.64	45.01
EBITDA	501.14	413.06	21.32
Other Income	41.85	77.34	-45.89
Finance Cost	100.82	85.14	18.42
Depreciation and amortisation	200.96	211.18	-4.84
Net Profit after tax	210.03	81.07	159.06

Consolidated Q1 FY27 at a glance **(Rs. In lacs)**

Particulars	Q1 FY27	Q1 FY26	Growth in %
Revenue from Operations	4230.94	3302.54	28.11
EBITDA	496.57	431.73	15.02
Other Income	41.85	63.09	-33.67
Finance Cost	100.81	85.38	18.07
Depreciation and amortisation	200.96	211.18	-4.84
Net Profit after tax	204.66	99.62	105.44

Q1 FY27 Revenue Break-up **(Rs. In lacs)**

Particulars	Q1 FY27	Q1 FY26	Growth in %
Domestic			
Branded Formulation	737.67	454.58	62.27
Branded Veterinary	587.35	296.90	97.83
P2P	1,327.09	1,536.69	-13.64
Total Domestic Sales	**2,652.11**	**2,288.17**	**15.91**
Exports			
Branded Formulation	1,483.42	882.85	68.03
Total Export Sales	**1,483.42**	**882.85**	**68.03**
Other Operating Income	95.41	131.52	-27.46
Consolidated Revenue from Operations	**4,230.94**	**3,302.54**	**28.11**
Other Income	41.85	63.09	-33.67
Consolidated Net Total Income	**4,272.79**	**3,365.63**	**26.95**

About Lyka Labs Limited:

Lyka Labs Limited is in the field of Manufacturing & Marketing of Finished Formulations for Human & Animal Healthcare across various therapeutic segments.

SHAILENDRA KUMAR AGRAWAL Digitally signed by SHAILENDRA KUMAR AGRAWAL Date: 2026.08.11 15:03:26 +05'30'

Shailendra Kumar Agarwal
Company Secretary